Ensysce Biosciences has filed a patent for a method of treating viral infections, specifically SARS-CoV-2 (COVID-19), using nafamostat mesylate. The patent claims that oral administration of nafamostat mesylate can reduce viral load in the gastrointestinal tract and associated symptoms. The method involves orally administering a therapeutically effective amount of nafamostat or its salt, with a plasma concentration below 5 ng/mL after 1 to 8 hours. GlobalData’s report on Ensysce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ensysce Biosciences, nanorobotics was a key innovation area identified from patents. Ensysce Biosciences's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230190697A1) describes a method for treating viral infections, particularly those caused by coronaviruses, using the drug nafamostat. The method involves orally administering a therapeutically effective amount of nafamostat or a pharmaceutically acceptable salt thereof to the subject. The patent claims that the amount of nafamostat measurable in the subject's plasma after 1 to 8 hours of administration should be below about 5 ng/mL.
The patent also specifies that the therapeutically effective amount of nafamostat is equivalent to the amount of nafamostat in about 100 mg to about 1500 mg of nafamostat mesylate. This effective amount can be administered to the subject in the form of solid oral dosage forms, such as tablets, capsules, or multiparticulates, containing about 50 mg to about 200 mg of nafamostat mesylate or an equivalent amount of nafamostat or a pharmaceutically acceptable salt thereof.
The method can be used to inhibit viral infections in subjects who have been exposed to a virus, including coronaviruses like SARS-CoV, MERS-CoV, and SARS-CoV-2. It is particularly relevant for subjects who are aged 65 or older or have underlying health conditions such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart failure, diabetes, or obesity. The administering of nafamostat can occur before the onset of symptoms, and the dosage can range from about 0.1 mg to about 20 mg of nafamostat mesylate per kg of the subject's weight per day.
Additionally, the patent claims a method of reducing the risk of adverse events associated with intravenous administration of nafamostat mesylate in subjects with viral infections. This is achieved by orally administering a therapeutically effective amount of nafamostat mesylate to the subject, thereby avoiding potential adverse events such as allergic reactions, diabetic ketoacidosis, agranulocytosis, and hyperkalemia.
In summary, the patent describes a method for treating viral infections, particularly those caused by coronaviruses, using the drug nafamostat. The method involves orally administering a specific amount of nafamostat or its salt to the subject, with the goal of inhibiting viral replication and reducing the risk of adverse events associated with intravenous administration. The method is particularly relevant for older individuals and those with underlying health conditions.
To know more about GlobalData’s detailed insights on Ensysce Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
